Outcome of second- and third-line Helicobacter pylori eradication therapies based on antimicrobial susceptibility testing.

Objectives: The objective of this study was to assess the outcome of antimicrobial susceptibility-guided therapies in Helicobacter pylori-infected individuals who had undergone unsuccessful prior eradication treatments.Methods: From October 2004 to December 2013, 481 H. pylori-positive patients with...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Antimicrobial Chemotherapy (JAC) Vol. 70; no. 11; pp. 3141 - 3146
Autores principales: Draeger, Sarah, Wüppenhorst, Nicole, Kist, Manfred, Glocker, Erik-Oliver
Formato: research tables/charts Journal Article
Publicado: Oxford University Press / USA Nov2015
Acceso en línea:Ver este registro en EBSCOhost
Descripción
Sumario:Objectives: The objective of this study was to assess the outcome of antimicrobial susceptibility-guided therapies in Helicobacter pylori-infected individuals who had undergone unsuccessful prior eradication treatments.Methods: From October 2004 to December 2013, 481 H. pylori-positive patients with prior unsuccessful eradication treatments were administered susceptibility-guided salvage eradication treatments. Six months on, treatment outcome was assessed by urea breath test, stool antigen ELISA, Helicobacter urease test or microbiology and/or histopathology.Results: Resistance to metronidazole and clarithromycin was high in patients with prior unsuccessful eradication treatments and was dependent on the number of treatment failures. Susceptibility-guided salvage eradication treatments achieved eradication rates of nearly 70% in these patients. No particular regimen was significantly better than another.Conclusions: Antimicrobial susceptibility testing prevents prescription of inefficient antimicrobials and enables individualized and promising salvage treatments in patients with prior unsuccessful eradication treatments.